Agency Forms Undergoing Paperwork Reduction Act Review, 5972-5973 [E7-2071]
Download as PDF
<![CDATA[
5972
Federal Register / Vol. 72, No. 26 / Thursday, February 8, 2007 / Notices
One important and effective means to
promote and support the initiation and
maintenance of breastfeeding is through
the health care system. While the few
studies on breastfeeding practices at
intra-partum care facilities in individual
states and facilities show significant
variation in practices, it is not currently
possible to assess and monitor
breastfeeding-related practices and
policies in hospitals and free-standing
childbirth centers across the United
States with data currently available.
CDC plans to conduct an assessment
of breastfeeding-related maternity care
practices in intra-partum care facilities
in the United States and Territories to
provide information to individual
facilities, state health departments, and
CDC on the extent to which facilities are
providing effective breastfeeding-related
maternity care. The assessment will
provide detailed information on general
facility characteristics related to
maternity care such as facility policies
related to breastfeeding-related
maternity care practices, practices
related to the training of health care staff
on breastfeeding instruction,
management and support, rooming-in,
infant supplementation, and discharge
from facility. CDC will provide facilityspecific information based on the
assessment to the individual facilities
and state-specific information to state
health departments. The information
from the survey can be used by facilities
to evaluate and modify breastfeedingrelated maternity care practices, and by
states and CDC to inform and target
programs and policies to improve
breastfeeding-related maternity care
practices at intra-partum care facilities.
Approximately 4,375 facilities
providing maternity care in the United
States and Territories will be mailed a
survey every other year in this study.
The survey will be administered for the
first time in 2007 and for the second
time in 2009. Survey content will be
similar in each of the administrations to
examine changes in practices and
policies over time. It is expected that
approximately 3,700 facilities will
complete the thirty-minute
questionnaire in each administration.
The facilities will be identified from the
American Hospital Association’s
Annual Survey of Hospitals (AHA) and
the National Association of
Childbearing Centers (NACC). A fiveminute screening telephone call will be
made prior to survey administrations to
all facilities identified as providing
maternity care in AHA and NACC to
ensure they are currently providing
maternity care, to identify possible
satellite clinics providing maternity
care, and to identify survey respondent
in each of the facilities. The respondents
will have the option of either
responding by mail or through a Webbased system. The survey will provide
detailed information about
breastfeeding-related maternity care
practices and policies at hospitals and
free-standing birth centers. There are no
costs to respondents other than their
time. The approximate annualized
burden hours are 1,484 hours.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Questionnaire/respondents
Screening call to facilities that have at least one
Mail survey/ facilities providing maternity care in
Screening call to facilities that have at least one
Mail survey/ facilities providing maternity care in
registered maternity bed (2006) ....................
the past calendar year (2006) .......................
registered maternity bed (2008) ....................
the past calendar year (2008) .......................
Dated: January 31, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–2070 Filed 2–7–07; 8:45 am]
Management and Budget, Washington,
DC or by fax to (202) 395–6974. Written
comments should be received within 30
days of this notice.
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30 Day–07–06BI]
jlentini on PROD1PC65 with NOTICES
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–4766 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
VerDate Aug<31>2005
15:58 Feb 07, 2007
Jkt 211001
Proposed Project
Determining Stakeholder Awareness
and the Use and Impact of Products
Developed by the Evaluation of
Genomic Applications in Practice and
Prevention (EGAPP) Model Project—
New—National Center for Chronic
Disease Prevention and Health
Promotion/National Office of Public
Health Genomics (NOPHG), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
More than 1,000 genetic tests are
currently available in clinical practice.
Most are used for diagnosis of rare
genetic diseases, but a growing number
have population-based applications, and
the potential for broad public health
impact.
A number of issues have been raised
about the current status of genetic
testing implementation, including the
need to develop evidence to establish
PO 00000
Frm 00014
Fmt 4703
Sfmt 4703
1458
1240
1458
1240
Average
burden per
response
(in hours)
Number of
responses/
respondent
1
1
1
1
5/60
30/60
5/60
30/60
validity and utility of genetic tests
before tests are commercialized.
Advisory panels, professional
organizations, and clinical experts have
produced recommendations on the
development and clinical
implementation of safe and effective
genetic tests. In response to the need for
a coordinated approach for effectively
integrating genomic tests into clinical
practice and health policy, CDC’s
National Office of Public Health
Genomics (NOPHG) initiated the
(Evaluation of Genomic Applications in
Practice and Prevention) EGAPP model
project in 2004 to establish a systematic,
evidence-based process for assessing
genetic tests in transition from research
to practice. To support this goal, an
independent, non-federal,
multidisciplinary EGAPP Working
Group was established to identify,
prioritize, and select genetic tests to be
reviewed; establish review methods and
processes; monitor progress of the
reviews; and develop conclusions and
recommendations based on the
evidence.
E:\FR\FM\08FEN1.SGM
08FEN1
5973
Federal Register / Vol. 72, No. 26 / Thursday, February 8, 2007 / Notices
The plan for surveying key
stakeholders described here represents a
large component of the overall project
evaluation plan. The study will be
conducted in collaboration with a
consultant, Judith L. Johnson, PhD,
under a CDC task order with the McKing
Consulting Corporation. Dr. Johnson
and McKing Consulting Corporation
worked with CDC on study design, and
will collect data for the study, conduct
data analyses, and develop written
reports of results.
The purpose of this study is to collect
information on the value and impact of
the EGAPP products developed and
disseminated (e.g., evidence reports,
recommendations) by surveying
members of key stakeholder groups
considered by project advisors to have
the most immediate need and interest in
EGAPP products. The four key
stakeholder groups are healthcare
providers, healthcare payers and
purchasers, policy makers (e.g., medical
professional organizations, healthcare
policy organizations), as well as targeted
consumer groups and Web site visitors.
Healthcare providers/payers have
expressed interest in evidence-based
information on emerging genetic tests,
and will receive the first surveys about
six months after the release of the first
evidence reports and EGAPP Working
Group recommendations; these groups
will be surveyed again one year later.
Policy makers, consumers, and
healthcare purchasers are likely to
identify and be impacted by information
developed by EGAPP over a somewhat
longer timeline. Therefore, these groups
will be surveyed twelve months after
the first products are released, and
surveyed again one year later. During
two specified periods of time one year
apart, individuals accessing the EGAPP
website will be given the option to
participate in an EGAPP survey.
There are no costs to the respondents
other than their time. The total
estimated annualized burden hours are
448.52.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Type of respondent
Survey name
Healthcare Providers:
Primary Care Providers ...........................
Specialists ................................................
Genetic Counselors .................................
Mid-level Practitioners .............................
Nurses ......................................................
Healthcare Payers and Purchasers:
Healthcare Payers ...................................
Healthcare Purchasers ............................
Healthcare Policy Makers ........................
Consumers:
Group members .......................................
Website visitors ........................................
Healthcare Provider Survey.
.........................................................................
.........................................................................
.........................................................................
.........................................................................
.........................................................................
jlentini on PROD1PC65 with NOTICES
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an
email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
VerDate Aug<31>2005
15:58 Feb 07, 2007
Jkt 211001
10/60
10/60
10/60
10/60
10/60
General Survey ..............................................
.........................................................................
385
385
1
1
Proposed Project
Background and Brief Description
Agency Forms Undergoing Paperwork
Reduction Act Review
100
50
Automated Management Information
System (MIS) for Diabetes Control
Programs (OMB No. 0920–0479)—
Revision—National Center for Chronic
Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
[30 Day–07–0479]
10/60
10/60
10/60
10/60
10/60
1
1
1
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
1
1
1
1
1
19 31
DC or by fax to (202) 395–6974. Written
comments should be received within 30
days of this notice.
The Division of Diabetes Translation
(DDT) within the National Center for
Chronic Disease Prevention and Health
Promotion, Centers for Disease Control
and Prevention (CDC), has implemented
a Management Information System
(MIS) and federally sponsored data
collection requirement for all CDC
funded Diabetes Prevention and Control
Programs. Diabetes is the sixth leading
cause of death in the United States,
contributing to more than 224,000
deaths each year. An estimated 14.6
million people in the United States have
been diagnosed with diabetes and an
estimated 6.2 million people have
PO 00000
Frm 00015
Fmt 4703
Sfmt 4703
Average
response per
respondent
385
385
200
385
385
Policy/Payer Survey .......................................
Purchaser Survey ...........................................
Policy Survey .................................................
Dated: January 31, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–2071 Filed 2–7–07; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Number of
responses per
respondent
undiagnosed diabetes. The Division of
Diabetes Translation provides funding
to health departments of States and
territories to develop, implement, and
evaluate systems-based Diabetes
Prevention and Control Programs
(DPCPs). DPCPs are population-based,
public health programs that design,
implement and evaluate public health
prevention and control strategies that
improve access to and quality of care for
all, and reach communities most
impacted by the burden of diabetes (e.g.,
racial/ethnic minority populations, the
elderly, rural dwellers and the
economically disadvantaged). Support
for these programs is a cornerstone of
the DDT’s strategy for reducing the
burden of diabetes throughout the
nation. The Diabetes Control Program is
authorized under sections 301 and
317(k) of the Public Health Service Act
[42 U.S.C. 241 and 247b(k)].
In accordance with the original OMB
approval (0920–0479) and the first
extension (August 14, 2003) for this
project, this requested revision will
continue to expand and enhance the use
of the technical reporting capacity of the
MIS for 3 years. The MIS is a Web-
E:\FR\FM\08FEN1.SGM
08FEN1
]]>Agencies
[Federal Register Volume 72, Number 26 (Thursday, February 8, 2007)]
[Notices]
[Pages 5972-5973]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-2071]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30 Day-07-06BI]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) publishes a
list of information collection requests under review by the Office of
Management and Budget (OMB) in compliance with the Paperwork Reduction
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call
the CDC Reports Clearance Officer at (404) 639-4766 or send an e-mail
to omb@cdc.gov. Send written comments to CDC Desk Officer, Office of
Management and Budget, Washington, DC or by fax to (202) 395-6974.
Written comments should be received within 30 days of this notice.
Proposed Project
Determining Stakeholder Awareness and the Use and Impact of
Products Developed by the Evaluation of Genomic Applications in
Practice and Prevention (EGAPP) Model Project--New--National Center for
Chronic Disease Prevention and Health Promotion/National Office of
Public Health Genomics (NOPHG), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
More than 1,000 genetic tests are currently available in clinical
practice. Most are used for diagnosis of rare genetic diseases, but a
growing number have population-based applications, and the potential
for broad public health impact.
A number of issues have been raised about the current status of
genetic testing implementation, including the need to develop evidence
to establish validity and utility of genetic tests before tests are
commercialized. Advisory panels, professional organizations, and
clinical experts have produced recommendations on the development and
clinical implementation of safe and effective genetic tests. In
response to the need for a coordinated approach for effectively
integrating genomic tests into clinical practice and health policy,
CDC's National Office of Public Health Genomics (NOPHG) initiated the
(Evaluation of Genomic Applications in Practice and Prevention) EGAPP
model project in 2004 to establish a systematic, evidence-based process
for assessing genetic tests in transition from research to practice. To
support this goal, an independent, non-federal, multidisciplinary EGAPP
Working Group was established to identify, prioritize, and select
genetic tests to be reviewed; establish review methods and processes;
monitor progress of the reviews; and develop conclusions and
recommendations based on the evidence.
[[Page 5973]]
The plan for surveying key stakeholders described here represents a
large component of the overall project evaluation plan. The study will
be conducted in collaboration with a consultant, Judith L. Johnson,
PhD, under a CDC task order with the McKing Consulting Corporation. Dr.
Johnson and McKing Consulting Corporation worked with CDC on study
design, and will collect data for the study, conduct data analyses, and
develop written reports of results.
The purpose of this study is to collect information on the value
and impact of the EGAPP products developed and disseminated (e.g.,
evidence reports, recommendations) by surveying members of key
stakeholder groups considered by project advisors to have the most
immediate need and interest in EGAPP products. The four key stakeholder
groups are healthcare providers, healthcare payers and purchasers,
policy makers (e.g., medical professional organizations, healthcare
policy organizations), as well as targeted consumer groups and Web site
visitors. Healthcare providers/payers have expressed interest in
evidence-based information on emerging genetic tests, and will receive
the first surveys about six months after the release of the first
evidence reports and EGAPP Working Group recommendations; these groups
will be surveyed again one year later. Policy makers, consumers, and
healthcare purchasers are likely to identify and be impacted by
information developed by EGAPP over a somewhat longer timeline.
Therefore, these groups will be surveyed twelve months after the first
products are released, and surveyed again one year later. During two
specified periods of time one year apart, individuals accessing the
EGAPP website will be given the option to participate in an EGAPP
survey.
There are no costs to the respondents other than their time. The
total estimated annualized burden hours are 448.52.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average
Type of respondent Survey name Number of responses per response per
respondents respondent respondent
----------------------------------------------------------------------------------------------------------------
Healthcare Providers: Healthcare Provider Survey. .............. .............. ..............
Primary Care Providers......... ........................... 385 1 10/60
Specialists.................... ........................... 385 1 10/60
Genetic Counselors............. ........................... 200 1 10/60
Mid-level Practitioners........ ........................... 385 1 10/60
Nurses......................... ........................... 385 1 10/60
Healthcare Payers and Purchasers:
Healthcare Payers.............. Policy/Payer Survey........ 100 1 10/60
Healthcare Purchasers.......... Purchaser Survey........... \19\ 31 1 10/60
Healthcare Policy Makers....... Policy Survey.............. 50 1 10/60
Consumers:
Group members.................. General Survey............. 385 1 10/60
Website visitors............... ........................... 385 1 10/60
----------------------------------------------------------------------------------------------------------------
Dated: January 31, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for Disease Control and
Prevention.
[FR Doc. E7-2071 Filed 2-7-07; 8:45 am]
BILLING CODE 4163-18-P
